logo

Email This Article


CTI BioPharma: FDA Extends Review Period For Pacritinib For Treatment Of Myelofibrosis; Stock Down
To Email: *
Bcc:   Seperate multiple addresses with commas(,)
Your Email: *
Format : 


* Denotes Required Fields
This information entered on this page will not be used to send unsolicited email, and will not be sold to a 3rd party.
This material may not be published, broadcast, rewritten or redistributed without prior written consent of RTTNews.